| Stefan Ståhl is Professor in Molecular Biotechnology,
and was appointed as Dean for the School of Biotechnology
in January 2005. |
| The major present focus for the group,
Biotherapy and Bacterial
Display is in evaluating affibody-mediated biotherapy
approaches. A novel class of affinity proteins, denoted
affibody ligands, has been developed at our department.
Their potential in various therapeutic settings are investigated,
including tumor targeting for medical imaging and radiotherapy
applications. In addition, a staphylococcal surface display system
has been developed by the group. The system has become a
platform for protein engineering application, using fluorescence
activated cell sorting (FACS) as a powerful analytical tool.
The system is presently evaluated for selection of affinity
proteins, i.e. affibody molecules and domain antibodies, using surface-displayed
libraries, as well as epitope mapping of polyclonal and
monoclonal antibodies. |
| Entrepreneural activities: Stefan is
cofounder of the biotech companies Creative Peptides AB
(1996), Affibody AB (1998) and Visual Bioinformatics AB
(1999). Between April 2000 and Dec 2002 he acted as Chief
Scientific Officer at Affibody AB, while the company grew
from four to 65 employees, still retaining PhD students
and research activity at KTH. |
| Scientific output: Stefan is the inventor
of a number of patents, and has published more than 160 scientific
papers in international peer-reviewed journals, and has
supervised 19 PhD students to their dissertation (see below). |
| Dissertations
from the group: |
| 1994 |
Stabilization of recombinant
proteins produced in E. coli. (co-supervised w.
M. Uhlén) |
Maria Murby |
Phadia AB |
| 1998 |
Recombinant subunit vaccines: protein immunogens,
live bacteria and nucleic acids |
Sissela Lijeqvist |
Karolinska Institutet |
| 1998 |
Design, selection and production of recombinant
proteins for the prevention of infectious diseases |
Marianne Hansson |
CEO, Atlas Antibodies AB |
| 1998 |
Strategies for vaccine development applied
to Plasmodium falciparum asexual blood-stage antigens
Pf332 and Pf155/RESA |
Diana Haddad |
Johns Hopkins, Baltimore, USA |
| 1999 |
Genetic design for facilitated production
of human peptide hormones in Escherichia coli |
Per Jonasson |
Affibody AB |
| 1999 |
Staphylococcal surface display and its applications
in bioscience |
Patrik Samuelson |
KTH (group leader) |
| 1999 |
Display of affinity proteins on bacteria
and bacteriophage" (Co-supervised w. Nygren) |
Elin Gunneriusson |
Affibody AB |
| 1999 |
Functional genomics and proteomics: analysis
of cDNA and encoded proteins |
Magnus Larsson |
CEO, Fiber-staden AB |
| 2000 |
Production and delivery of recombinant subunit
vaccines |
Christin Andersson |
AstraZeneca |
| 2002 |
Functional Proteomics: generation and analysis
of cDNA-encoded proteins |
Susanne Gräslund |
SGC, Toronto |
| 2002 |
Engineering of staphylococcal surfaces for
biotechnological applications |
Henrik Wernérus |
Atlas Antibodies |
| 2005 |
Rational and combinatorial protein engineering
for vaccine delivery and drug targeting |
Maria Wikman |
Peviva AB |
| 2008 |
Staphylococcal surface display for protein
engineering and characterization |
John Löfblom |
KTH (PostDoc) |
| 2008 |
Affibody molecules for proteomic and therapeutic
applications |
Caroline Grönwall |
NYU, USA |
| 2008 |
Affibody molecules targeting the epidermal
growth factor receptor for tumor imaging applications |
Mikaela Friedman |
Uppsala Univ.
(VR-PostDoc) |
| 2009 |
Development of molecular recognition by rational
and combinatorial engineering |
Andreas Jonsson |
KTH
(VR-PostDoc) |
| 2009 |
Staphylococcal surface display in directed
evolution |
Nina Kronqvist |
Karolinska Institutet |
| 2011 |
Intracellular systems for characterization and engineering of proteases and their substrates (co-supervised with P. Samuelson) |
George Kostallas |
Karolinska Institutet |
| 2011 |
Design and evaluation of radiolabeled affibody tracers for imaging of HER2-expressing tumors. |
Helena Wållberg |
KTH |
